Acute lymphoblastic leukemia (ALL) is diagnosed in approximately 100 000 people worldwide per year and 70% of the patients are children. Most children have a good prognosis, as almost 80% will be cured, however only 30% of adults are cured. Additionally, the current chemotherapies have longlasting and severe side-effects. These findings indicate that the search for better and safer treatment modalities for ALL is still important. As leukemia directly affects the human immune cells, immunotherapeutic approaches have long been ignored as treatment options for this disease. However, increased knowledge of the immune system has opened new opportunities for immune modulation that could be of benefit to leukemia patients. Several recent advances towards immunotherapy of ALL will be discussed. Leukemia (2001) 15, 701-706.
Introduction
Leukemia is a heterogeneous group of hematopoietic disorders and represents 30% of all childhood cancers. Acute lymphoblastic leukemia (ALL) accounts for 75-80%, acute myeloid leukemia (AML) for 15-20% and chronic myeloid leukemia (CML) for only 2-3% of all newly diagnosed childhood leukemia cases. 1, 2 Through improved chemotherapy protocols, around 80% of all children diagnosed with ALL reach a complete remission. However, 30% of ALL is diagnosed in adults and their cure rate of 30-40% is significantly lower than in children. In most cases, minimal residual disease or relapse has to be treated with more aggressive chemotherapy or bone marrow transplantation. 3 The toxicity of curative chemotherapeutic strategies is especially severe for the heart and brain in children. The long-term complications and damaged physical and intellectual development significantly compromise the quality of life of long-term survivors. Moreover, increases in new malignancies after leukemia treatment have been diagnosed. Two-thirds of all ALL is diagnosed in children under 15 years of age. Precursor B lineage ALL is the most common pediatric leukemia and has an age-associated incidence peak at around 2-10 years. 4 Every year 2400 new cases are diagnosed with ALL in the USA. In western countries the development of combination chemotherapy and bone marrow transplantation has increased the cure rate of childhood ALL to greater than 70% in many centers. 5 As ALL is a heterogeneous disease, a uniform therapy is not available. In contrast, a careful risk prognosis has to be made at the time of diagnosis.
Clonal chromosomal abnormalities have been detected in 80-90% of the cases of ALL. 6 The accurate identification of chromosomal abnormalities plays a key role in the diagnosis, prognosis and treatment assignment of leukemia patients. The most common genetic alteration in childhood ALL is the TEL/AML1 fusion gene, created by the chromosomal translocation t (12;21) . 7 The TEL/AML1 fusion gene is detected in approximately 30% of the cases. 7 The other genetic alterations of childhood ALL are: hyperdiploidy in 25% of the cases, translocation t(4;11) (MLL-AF4 gene fusion) in 5% of the cases and others in 40% of the cases. 8 The t(9;22) translocation results in the expression of BCR/ABL fusion protein and is detected in 2-6% of the childhood ALL cases. This leukemia subgroup is better known as the Philadelphia chromosomepositive (Ph+) ALL, which is considered one of the molecular markers associated with a particularly high risk of treatment failure. [9] [10] [11] In adult ALL the TEL/AML 1 translocation is hardly detected (2%), but the high percentage of unfavorable BCR/ABL (25%) and MLL (7%) rearrangements and random genetic instability (40%) significantly contribute to the poor prognosis in adults. 5 On the other hand the genetic rearrangements may result in unique proteins that can serve as suitable targets for novel immunotherapeutic approaches.
Immunotherapy
The activation of the immune system against tumors is still under investigation. Immune surveillance against tumors is a widely used term, however the impact and even the presence of such a function of the immune system is still debated. Increased tumor incidence in immune suppressed individuals can be used to justify a role of the immune system in the protection against cancer, however a close examination of the cancers in these individuals reveals mainly an increased incidence of virus-induced tumors. In addition, the spontaneous regressions observed in some patients with melanoma and renal cell carcinoma also indicate a role of the immune system in tumor rejection. Most tumors however are not rejected and seem able to prevent immune activation or escape from recognition by the immune cells. 12 The fact that the immune system is not immediately activated against the malignant cells, however, does not mean that it cannot be activated at all against the tumors. Immunotherapy of cancer aims at such activation.
In the last decade, specific immune activation against tumors has been successfully demonstrated. The inventive minds of researchers have resulted in an uncountable variety of approaches to activate or employ the immune system against tumors from bacterial BCG to IL-2 to antibodies via peptides to DNA vaccines. 13 Increased knowledge on activation of the immune system and immune escape of tumors has paved the way for advanced approaches to treatment of tumors. However, a tumor-specific or tumor-associated protein that can serve as a tumor rejection antigen is still a requirement to assure tumor-specific activation and elimin-ation of the tumor by the immune system.
14 Most tumor cells and especially leukemias express such antigens due to genetic alterations and chromosome instability. 15 A major concern, however, is the induction of tolerance against tumor cells. Tolerance induction is a continuous process in the body to maintain homeostasis by prevention of immune responses against self-antigens. However, tumors may also induce tolerance by presentation of antigens to T cells in the absence of the proper costimulatory molecules. In order to induce immunity, foreign antigen presentation by specialized antigen presenting cells (APCs), like dendritic cells (DCs), is required. As oncogenesis is a gradual transformation process from normal cells to tumor cells it may not alert the immune system resulting in ignorance. It is currently unknown what exactly happens during the tumor formation, however effective immune activation does not seem to occur very frequently. As mentioned above, there is evidence that the immune system can play a role in tumor rejection and the goal of immunotherapy is to direct and enhance an immune response against the tumor.
The immune responses against tumors are mainly T cellmediated. CD8
+ cytotoxic T cells (CTLs) are the classical 'killer' cells, whereas the CD4 + T cells perform a helper function. T cells exist as inactive precursors in the immune system and must be activated to develop cytotoxicity. CTLs against tumors can be primed in a direct and indirect pathway. When the tumor cell expresses immunogenic antigens and MHC class I and costimulatory molecules, such as CD80, CD86 and CD40, the T cell can be primed by the tumor cells directly. However the majority of tumors lack costimulatory molecules and the activation of a T cell response is dependent on cross priming. Professional APCs, like DCs, have the capability to take up necrotic and apoptotic cells, process the antigens expressed by these cells and present them to T cells. 16, 17 APCs have to be 'licensed' by T helper cells to activate naive CTLs. The specific T helper cell binds with its CD40 ligand (CD40L/CD154) molecule to the surface receptor CD40 of the APC. This trigger of CD40 is absolutely required to activate or to license the APC. 18 Anti-CD40 antibodies or soluble CD40L can replace the CD40L ligation of APC by CD4 + T helper cells. 19, 20 Upon CD40-CD40L interaction, the APC upregulates MHC expression, cytokine production, especially interleukin 12 (IL-12) and costimulatory molecules, like CD80. Recognition of the antigen presented in the MHC class I of the licensed APC by the T cell receptor and ligation of CD28 with the CD80 or CD86 on the APC will prime the CTL and induce proliferation.
The ALL blast as antigen presenting cell
Induction of ALL-specific T cells requires presentation of ALLderived antigens by APCs. As mentioned above cross priming is the most likely mechanism for induction of antitumor immunity. However it would be much more efficient if the tumor cells could directly prime the encountered T cells, especially as the cells reside in the same hematopoietic and lymphatic compartments and contain all possible tumor antigens. Cardoso et al 21 have investigated the APC function of ALL cells. 21 Phenotypic characterization of ALL cells showed that ALL cells express both class I and class II MHC molecules, enabling presentation of their tumor antigens to both CD8 + and CD4 + T cells. However, they express no or only low levels of adhesion and costimulatory molecules. Presentation of antigens in the absence of costimulation induces a state of anergy, a form of tolerance, in T cells. CD80 was absent and CD86 was expressed on approximately 50% of the ALL. Proliferation experiments revealed that only CD86-expressing ALL cells were occasionally able to induce low levels of T cell proliferation. CD80 and CD86 negative ALL cells were never capable of inducing CTL proliferation. Moreover, the study confirmed that pre-B ALL cells that lack CD80 and CD86 induced T cell anergy. It may be possible that ALL cells, in part, escape immune destruction by induction of tolerance due to lack of costimulatory molecules. In an attempt to induce the activation of T cells by ALL cells, several strategies can be employed to provide the costimulatory signals. Proliferation assays showed that the CTL proliferation against CD80 negative ALL cells significantly increased when anti-CD28 monoclonal antibodies were added. As CD28 is the ligand on the T cell that binds to the CD80 molecule, this illustrates the importance of CD80 in the priming process. In another attempt to compensate for the absence of costimulatory molecules, ALL cells were incubated with CD40 ligand expressing fibroblasts to deliver a CD40 signal to ALL cells ( Figure 1 ). This was possible because 40% or more of the ALL cells expressed the CD40 antigen. T cell proliferation responses against the CD40L stimulated ALL cells were significantly better than against unstimulated ALL cells. In addition, immunophenotypic analysis showed upregulated expression of MHC I, MHC II, ICAM-1, LFA-3, CD80 and CD86 by ALL cells after CD40 mediated activation (Figure 1 ). The upregulation of important costimulatory molecules as a result of CD40 ligand stimulation significantly improved the APC function of ALL cells. 21 However, the APC function of pre-B ALL cells was only measured in proliferation assays. Lysis of ALL cells by CTLs was not reported. Results obtained in AML where DCs were generated from AML cells by incubation with CD40L also indicate the importance of antigen presentation for induction of antileukemic immune responses. Cocultivation of these CD40L-induced DCs with autologous lymphocytes resulted in specific lysis of autologous leukemia cells. 22 The observation that activation of CD40 provides a more complete APC function is in agreement with the license theory discussed above that shows the necessity of APC activation for T cell priming (Refs 23, 24 and Figure 1) .
In addition to the in vitro experiments, murine in vivo data are available on the induction of anti-tumor responses against a pre-existing ALL using CD40L alone or in conjunction with IL-2. 25, 26 In the latter study mice were challenged with B-ALL cells on day 1. On days 4 and 10 CD40L and IL-2 transfected fibroblasts were mixed with tumor cells and injected at a distant site. Results showed that a specific immune response against the B-ALL cells was induced after immunization with CD40L expressing fibroblasts. Furthermore, the combination of CD40L/IL-2 immunization amplified the anti-leukemic immune response and increased survival rates and rejection of the growing ALL tumors. Depletion of effector cell subsets indicated that CD4 + T cells, CD8 + T cells and natural killer cells all contributed to the anti-ALL response. 26 However, the in vivo results were different from the results observed in vitro in that tumor cells collected from the tumor site after CD40L stimulation did not show upregulation of MHC, CD80 or Fas molecules. The antigen presentation and T cell activation mechanisms induced by the CD40L expressing fibroblasts in this model are at present unclear.
A more straightforward approach to direct T cell priming by the ALL cells is transfer of costimulatory proteins into the tumor cells and use of these cells for antigen presentation of ALL-derived tumor antigens. Stripecke et al [27] [28] [29] have pursued this in several models. Murine in vivo experiments in a Philad-
Figure 1
The leukemia cell as antigen presenting cell (APC). In order to increase the induction of leukemia-specific T cell responses, several approaches have aimed to optimize antigen presentation by the leukemia cells. The activation of the leukemia cells can be achieved through CD40 with CD40 ligand either on a T cell, a fibroblast or as anti-CD40 antibodies or soluble CD40 ligand. The resultant increase in expression of MHC class I, class II, costimulation molecules CD80 and CD86 as well as adhesion molecules ICAM-1 and LFA-3 will allow activation of cytotoxic T lymphocytes (CTL) against MHC class I expressing leukemia cells. Other forms of improved antigen presentation by leukemia cells involve introduction of CD80 and/or CD86 into the cells.
elphia chromosome expressing ALL model showed that injection of ALL cells transduced to express CD80 induced T cell mediated rejection of the ALL while untransduced cells grew progressively. 27 Additionally, rejection of parental (CD80-negative) tumors could be induced by vaccination with CD80-transduced ALL cells and more importantly existing parental tumors could be rejected by therapeutic injection of the CD80 expressing ALL cells. 28 Although it was not formally shown in this model that the immune response was directed against the p185 BCR/ABL oncogenic fusion it is likely that this is a rejection antigen for this ALL. The possibility to induce an immune response against the BCR/ABL translocation in ALL would be very important because 25% of adult patients present with BCR/ABL positive ALL, which has an extremely poor prognosis. 5 These promising murine data could lead to clinical application when human ALL can be transduced efficiently. This has not been an easy task, but by using HIV-derived lentivirus-based vectors, Stripecke et al 29 have been able to transduce 40-90% of primary human ALL cells with CD80 and GM-CSF and show that these cells induce CD80-dependent proliferation of autologous T cells against the ALL. Taken together these data indicate that using the ALL cells as direct antigen presenting cells opens new possibilities for specific immunotherapeutic treatment of ALL.
Vaccination against TEL/AML1 positive pre-B ALL cells
The previous section discussed the use of tumor cells as antigen presenting cells of their endogenous tumor antigens. This is a feasible approach if no tumor antigens for the particular tumor have been identified. The advantage is that multiple antigens will be presented and can serve as rejection antigens for the tumor. However, when a tumor antigen is known, specific vaccination strategies against this antigen could be used to trigger a tumor specific immune response. Viral antigens in tumors are known to be tumor specific antigens (eg HPV 16/18 E6 and E7 in cervical carcinoma) and serve as useful Leukemia targets for vaccination. 30 However, translocation products expressed in leukemia cells are also promising candidates as tumor antigens. Previous studies showed that leukemogenesisassociated fusion proteins, such as BCR/ABL 31, 32 and PML/RAR␣, 33 have antigenicity and can act as leukemiaspecific antigens. Yotnda et al 34 reported for the fist time that the TEL/AML 1 fusion product of chromosomal translocation t(12;21) in human leukemias could also act as a specific tumor antigen. The protein formed by the TEL/AML1 fusion due to the t(12;21) is unique and therefore likely to be immunogenic. This suggests that specific CTLs against the TEL/AML1 fusion protein, primarily associated with childhood ALL, can be identified. Yotnda et al 34 could activate human T cells in vitro against the HLA-A2-restricted peptide R9M (RIAECILGM), derived from the fusion region AMPIGRIAECILGMNPS of TEL/AML1. Two TEL/AML 1 specific CD8 + CTL clones were generated, one from bone marrow (BM) of an ALL patient and one from BM of a healthy donor. Both CTL clones lysed R9M-pulsed HLA-matched donor cells and, more importantly, also HLA-matched ALL tumor cells and HLA-A2.1+-transfected REH cells endogenously expressing the TEL/AML1 protein.
The authors concluded that a TEL/AML1 fusion protein derived peptide was presented by HLA-A2 molecules, and therefore represented a potential target for specific cellmediated immunity against t(12;21) expressing ALL. The majority of patients with the translocation t(12;21) have identical breakpoints, which results in exactly the same fusion protein. 7 Therefore, a peptide as described here may be of use in many patients expressing the HLA-A2 haplotype. Occasionally TEL/AML1-specific CTLs are found in patients, indicating that TEL/AML1 anti-ALL CTLs can be naturally primed. 34 In addition, two CD4 + T cells clones generated from healthy donors recognized peptides containing the same TEL/AML1 fusion protein derived RIAECILGM epitope. 35 Blocking experiments and proliferative responses of the CD4 + T cell clones against the peptide and the recombinant TEL/AML1 protein demonstrated that this TEL/AML1 epitope was recognized and that the clones were restricted by HLA-DP5 and HLA-DP17, respectively. 35 Cytotoxicity assays showed that the CD4 T cell clones could kill peptide-loaded cells. However, T cell responses against pre-B ALL cells or DCs that had engulfed UV-induced apoptotic leukemia cells could not be demonstrated. Based on these results it is not clear whether the TEL/AML1-specific CD4 T cells play an important role in the eradication of TEL/AML1 expressing ALL cells. Their presence, however, may be crucial for the induction of TEL/AML1-specific CTL as secretion of type I helper cytokines was detected upon recognition of the TEL/AML1 peptide in the context of MHC-class II molecules. Similar results have been obtained against the BCR/ABL translocation fusion protein p210 in CML where both CD8
+ and CD4 + T cells have been identified against the translocation product. 31, 32 These combined data indicate that translocation fusion proteins in leukemias can serve as targets for tumor immunotherapy.
Adoptive T-cell immunotherapy for pre-B ALL
Treatment of ALL relapses after failure of remission induction therapy is generally unsuccessful. 5 Novel adoptive T cell immunotherapy as a treatment for immunosuppressed patients with viral infections such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), and patients infected with human immunodeficiency virus (HIV-1) has shown great promise. [36] [37] [38] [39] [40] Antiviral antigen-specific CTLs and T cell clones have been generated ex vivo, and adoptively transferred to patients with acute infections leading to impressive clinical results. Furthermore, in cancer patients with melanoma, non-Hodgkin's lymphoma and CML similar results have been observed. [41] [42] [43] [44] [45] [46] These results indicate that adoptive T cell therapy could be explored to treat minimal residual disease to prevent relapses in pre-B ALL. This alternative would reduce the intensity of conventional therapy and probably decrease non-specific and organ-specific toxicity.
Autologous anti-pre-B ALL specific CD8 + CTLs were generated in vitro from the bone marrow of 10/15 (66%) patients with pre-B ALL. 47 The generation of the autologous antileukemia CTLs was only possible through costimulation via CD28. This study confirmed previous results addressing the need to enhance the APC function of ALL cells for induction of ALL-specific T cell responses. The anti-leukemia CTLs did not lyse non-malignant autologous BM cells and the CTLs lacked cross-reactivity against allogenic pre-B leukemia cells indicating the specificity of the CTLs. The CTL population contained both CD4
+ and CD8 + positive CTLs, but the CD8 + CTL population was consistently two-fold higher than the CD4 + population. In addition to this study, a preclinical study has indicated that the predominantly CD8
+ autologous anti-leukemia CTLs are appropriate for adoptive T cell transfer. 48 The CD8 + CTLs were able to circulate, migrate through endothelium, home to the bone marrow microenvironment and most importantly, lyse leukemia cells in a microenvironment that favors tumor cell survival and proliferation without significant cytolysis of the stromal cells. The capacity to lyse leukemia cells in the presence of stroma is an important finding as previous studies 49, 50 reported that direct contact with BM stroma facilitates the in vitro adhesion-dependent survival of B ALL cells. 49 This results in a selective survival and proliferative advantage for the leukemia cells. In addition, lysis of ALL cells was suppressed in the presence of bone marrow stromal layers. 50 This indicated that the in vivo ALL cells adhered to stromal cells are more difficult to kill than ALL cells in vitro.
Bone marrow transplantation has been shown to be a successful treatment against leukemia. However, the balance between graft-versus-host disease (GVHD), a life-threatening complication, and leukemia relapse are important limitations of the treatment. The success of BMT was partly due to the presence of donor T cells in the BM grafts. The donor T cells contributed to the therapeutic effect by elimination of residual host leukemic cells in the patient's BM. 51 Depletion of the T cells from the allogenic bone marrow graft to reduce the occurrence of GVHD resulted in increased leukemia relapses. 51 Several studies have shown that specific CTLs directed against human minor histocompatability antigens (mHags) play a major role in the graft-versus-leukemia (GVL) and graft-versus-host reaction after HLA-matched bone marrow transplantation.
51-57 GVL reactivity is not observed in transplantation between identical twins in which anti-mHags responses are lacking. 51 Human mHags are polymorphic antigens that are inherited independent from HLA and they show either a broad or a restricted tissue distribution. [52] [53] [54] [55] [56] [57] CTLs against the mHags can be isolated from the blood of MHCmatched allogenic bone marrow transplant recipients. [52] [53] [54] [55] [56] mHags are expressed on hematopoietic cells, including leukemic cells, but not on cells derived from GVHD targets such as fibroblasts, keratinocytes or liver cells. 53, 55, 58 These observations suggest that the tissue-restricted mHags could serve as targets for T cell immunotherapy after BMT to enhance the elimination of the residual leukemia with a relatively low risk of GVHD. The mHags HA-1 and HA-2 are expressed exclusively on hematopoietic cells and induce HLA-A*0201 restricted CD8
+ CTLs, that effectively lyse leukemia cell precursors, circulating myeloid leukemia cells and circulating lymphoid leukemia cells. [53] [54] [55] The specific CD8 + CTLs did not lyse fibroblasts, keratinocytes or liver cells. 55 Recently, the HLA-A*0201 restricted peptide sequences of HA-1 and HA-2 antigens have been identified. 56 Mutis et al 59 used the HA-1 and HA-2 peptides loaded on DCs, as APCs, to stimulate autologous unprimed CD8 + T cells in vitro from mHag HA-1-and/or HA-2-negative healthy blood donors. Using this method sufficient numbers of CTLs could be generated for adoptive therapy purposes. In addition, these CTLs appeared more effective than when generated against peptide loaded peripheral blood mononuclear cells or monocytes and efficiently lysed leukemia cells derived from ALL and AML patients without reactivity against non-hematopoietic cells. Addition of IFN␥ during the CTL induction increased the yield, probably as a result of elevated MHC expression and improved APC function of the ALL cells.
Transformed B cells and B cell tumors exclusively express the HB-1 mHag, 60 mature untransformed CD40-stimulated B cells do not express HB-1. Therefore, HB-1 seems to be a B cell leukemia specific antigen. The mHag HB-1 gene is mainly expressed by B cell ALL cells and EBV-transformed B cells. 60 The mHag HB-1 was recognized by a CD8 + CTL clone derived from peripheral blood of an acute lymphoblastic B cell leukemia patient treated with HLA-matched BMT. 58 The specific HLA-B44 restricted CD8
+ CTLs lysed leukemia cells and EBVtransformed B cells, but not untransformed B cells. Moreover, the CTLs also did not lyse PHA-stimulated T cell blasts, monocytes and fibroblasts. These pre-clinical results on induction and adoptive transfer of ALL specific T cells certainly justify optimism for future use of these T cells to combat ALL.
Conclusions
In this review, the role of the immune system against ALL and the possibilities of immunotherapy for the treatment of ALL have been discussed. Until recently immunotherapy was not regarded as a treatment option for ALL, but the data in this review certainly indicate possibilities for the future. The lack of costimulatory molecules on ALL cells does, in part, explain their escape from immune destruction. Therefore, attempts have been focused on the APC function of ALL cells in order to improve CTL induction both in vivo and in vitro. Target antigens for immunotherapeutic approaches like the TEL/AML1 fusion protein and Hags open possibilities for ALL specific vaccination approaches. Additionally, the induction and adoptive transfer of autologous ALL recognizing CTLs are certainly treatment options, but need further clinical testing. In conclusion, immunotherapy could be an effective therapy against minimal residual disease to prevent relapses in ALL.
